Reducing the Global Breast Cancer Burden: The Importance of Patterns of Care Research

Albain, Kathy S.; Salazar, Jaime de; Aapro, Matti; Bergh, Jonas; Caleffi, Maira; Coleman, Robert E.; Eiermann, W.; İçlı, Fikri; Pegram, Mark D.; Piccart, Martine; Snyder, Raymond; Toi, Masakazu; Hortobágyi, Gabriel N.

doi:10.3816/cbc.2005.n.045

Cited by 19 publications

(15 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast carcinoma is the most common female cancer and among the most frequent causes of cancer mortality in women worldwide [1, 2]. Metastatic breast cancer is considered incurable with median survival estimates of about 2 to 3 years, but treatments with endocrine, cytotoxic, or targeted therapies can improve or maintain the quality of life and prolong survival.…”

Section: Introductionmentioning

confidence: 99%

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

2014

View full text Add to dashboard Cite

Background. We report our experience with vinorelbine, a widely used chemotherapeutic, in unselected metastatic breast cancer patients treated in clinical routine. Patients and Methods. The data of all patients with metastatic breast cancer receiving vinorelbine with or without trastuzumab during a six year period were reviewed. Patients received vinorelbine intravenous 25–30 mg/m2 or 60–80 mg/m2 orally in days 1 and 8 of a 21 day cycle. Results. Eighty-seven women were included. Sixty-two patients received vinorelbine alone and 25 patients received vinorelbine in combination with trastuzumab. In 67 patients this was the first line treatment for metastatic disease and in 20 patients it was 2nd or later line of treatment. The median TTP was six months (range: 1–45). The median overall survival was 11.5 months (range: 1–83). Seventy patients were evaluable for response. In patients receiving first line treatment 44.4% had a response while in the second and subsequent lines setting 12.5% of patients responded (P = 0.001). Objective response was obtained in 63.6% of patients receiving concomitant trastuzumab and in 25% of patients receiving vinorelbine alone (P = 0.0002). Conclusion. This study confirms a high disease control rate. Response rate and TTP were superior in first line treatment compared to subsequent lines.

show abstract

Section: Introductionmentioning

confidence: 99%

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

2014

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the most common malignant disease and among the most frequent causes of cancer mortality in females worldwide [1,2]. Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in 20-25% of invasive breast cancers, which is associated with a poor prognosis [3,4].…”

Section: Introductionmentioning

confidence: 99%

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients

Aitelhaj

Rais

et al. 2013

BMC Res Notes

View full text Add to dashboard Cite

BackgroundTrastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER 2) and inhibits carcinoma cellular proliferation. Its use as an adjuvant for a period of one year is currently an internationally recognised standard for the treatment of localized breast cancer. Its use is generally well tolerated, with the most salient side effect being a particular cardiotoxicity that is typically manifested by an asymptomatic decrease in the left ventricular ejection fraction (LVEF) requiring careful monitoring before and during treatment. To evaluate the cardiac safety of trastuzumab we conducted a retrospective observational study of patients with HER2-positive localized breast cancer treated with trastuzumab between May 2008 and May 2010 in Morocco.FindingsThe study comprised of 100 patients. The average in LVEF before the start of trastuzumab was 70%, and at the end of treatment 66%, a decrease in absolute terms of 4%; this difference was statistically significant. 38% of the patients exhibited cardiotoxicity. 97% of our patients have completed treatment, of whom 23% with a provisional arrest because of a regressive fall in LVEF. A final arrest has been made in 3% of cases due to a non regressive reduction in LVEF. A symptomatic heart failure was found in three patients. Analysis of risk factors toxicity found a baseline LVEF higher in the patients who met cardiotoxicity than the rest of our sample.ConclusionsThe cardiac safety in our study seems comparable with the literature data but located in the upper range of levels of toxicity. Cardiotoxicity is the major complication of Trastuzumab, of which LV dysfunction is the most common. Most instances are transient, asymptomatic and reversible.

show abstract

“…1,2 Median survival from diagnosis of metastatic disease is 2 to 3 years, with 5% to 10% survival beyond 5 years. 1,2 Median survival from diagnosis of metastatic disease is 2 to 3 years, with 5% to 10% survival beyond 5 years.…”

Section: Introductionmentioning

confidence: 99%

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

Albain

Nag²,

Calderillo-Ruiz³

et al. 2008

JCO

Self Cite

379

245

View full text Add to dashboard Cite

show abstract

Reducing the Global Breast Cancer Burden: The Importance of Patterns of Care Research

Cited by 19 publications

References 66 publications

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

Contact Info

Product

Resources

About